Dr. Magdalene Moran is the Chief Executive Officer of Topo Therapeutics. She is a highly accomplished biotechnology executive with more than 20 years’ experience leading drug discovery efforts directed against transmembrane protein targets implicated in pain, pulmonary, CNS and renal diseases. These efforts have culminated in the advancement of 4 programs from inception into clinical trials with large pharma partners. Most recently, Dr. Moran was the President and Chief Scientific Officer of Caraway Therapeutics, where she built out operations, drove scientific strategy, and led drug discovery efforts for multiple lysosomal ion channel targets from the company’s inception through its acquisition by Merck in November 2023. Dr. Moran started her career and held positions of increasing responsibility at Hydra Biosciences, a biotechnology company focused on various ion channel drug targets. She received her PhD in Neurobiology from Harvard University where she was advised by ion channel expert Dr. David Clapham.